Ci Circulating t g tumor or D DNA e A expos osure i in p - PowerPoint PPT Presentation

Ci Circulating t g tumor or D DNA e A expos osure i in p peripheral b blood ood using a novel process: Early y results of a liquid biopsy y feasibility y study J Douissard 1 , F Ris 1 , M Hellan 2 , J Ouellette 2 , NC Buchs 1 , L Buehler 1 , F Triponez 1 , C Toso 1 1 Geneva University Hospital and Medical School, Geneva, Switzerland 2 Wright State University, Ohio, USA

DISCLOSURES § Non-financial aid from Intuitive Surgical Inc. § Research grant from Intuitive Surgical Inc. § Consulting for Verb Surgical Inc.

BACKGROUND: RELEVANT CANCER MORTALITY WITH STAGE AT DIAGNOSIS 5-years-survival - SEER 1 database 1 Surveillance, Epidemiology and End Results database, National Institute of Health, USA

BACKGROUND: SCREENING LIMITATIONS

BACKGROUND: LIQUID BIOPSY - PRINCIPLES

BACKGROUND: LIQUID BIOPSY – A WORKING CONCEPT GUARDANT 360 QUANTGENE PLATFORM FOUNDATION ONE - In development LIQUID - Revolutionized Technology Stack - Panel of > 200 genes & > 70 000 locations - Commercially available - Aiming at the highest possible accuracy - Lower sensitivity essays targeted at to accommodate wide early cancer later stage cancers detection - Tumor genotyping for treatment information

METHODS: THE QUANTGENE PLATFORM

METHODS: DRAWING THE CUTOFF 1000 100 Probability score 10 1 0 2 4 6 8 10 12 14 16 18 20 Patient

METHODS: DRAWING THE CUTOFF 1000 100 Probability score 10 1 0 2 4 6 8 10 12 14 16 18 20 Patient

METHODS: DRAWING THE CUTOFF 1000 100 Probability score 10 1 0 2 4 6 8 10 12 14 16 18 20 Patient

METHODS: STUDY DESIGN

Enrolled to date: RESULTS Total: 2944 Cancer : 942 Controls: 2002 Processed with Quantgene Technology: PATIENTS Total : 154 ENROLLMENT Cancer: 67 Controls: 87 22 samples excluded Samples analyzed: Total: 132 Cancer: 56 Colorectal: 33 Pancreas: 23 Controls : 76

RESULTS Tumor Stage Patients Correctly Stage (n) identified specific individuals sensitivity (n) (%) STAGE SPECIFIC SENSITIVITY: I 6 6 100 II 6 6 100 COLORECTAL III 13 11 84.6 CANCER IV 6 6 100 Not applicable/Unknown 2 1 50 Total 33 30 90.9

RESULTS Tumor Stage Patients Correctly Stage (n) identified specific individuals sensitivity (n) (%) STAGE SPECIFIC SENSITIVITY: I 2 2 100 II 6 6 100 PANCREATIC III 8 7 87.5 CANCER IV 5 5 100 Not applicable/Unknown 2 1 50 Total 23 21 91.3

RESULTS Control patients Correctly identified Specificity (n) (n) (%) 76 72 94.7 Overall test sensitivity 91.1 SPECIFICITY & OVERALL Overall test specificity 94.7 PERFORMANCE Positive predictive value 93.0 Negative predictive value 93.5

CONCLUSION: APPLICATIONS FOR SURGERY & BEYOND

THANK YOU! Jonathan.Douissard@hcuge.ch